

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Patient Selection Criteria for Initial 2-Week Trial of Powered NPWT

Based on review of available data, the Company may consider initial 2-week therapeutic trial of powered negative pressure wound therapy (NPWT) system to be **eligible for coverage**** when patient selection criteria are met:

- NPWT is part of a comprehensive wound care program that includes controlling contributing factors, e.g., diabetes, nutrition, relief of pressure; **AND**
- NPWT is requested for any of these wound types:
 - o Stage III or IV chronic open wounds (diabetic or pressure ulcers) that meet following requirements:
 - Present for at least 30 days; **AND**
 - Have failed to heal despite optimal wound care; **AND**
 - High-volume drainage interferes with healing and/or standard dressing cannot be maintained; **OR**
 - o Traumatic or surgical wounds that meet following requirements:
 - Failure of immediate or delayed primary closure; **AND**
 - Presence of exposed bone, cartilage, tendon, or foreign material within the wound; **OR**
 - o Other problematic wounds in patients with clinical conditions known to negatively impact wound healing that meet following requirements:
 - Nonhealing (at least 30 days) despite optimal wound care; **AND**
 - Require accelerated formation of granulation tissue that cannot be achieved by other available topical wound treatments; **AND**
 - One of the following conditions is present:

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

- Significant risk of infection, such as wound location; **OR**
- Immunocompromised status; **OR**
- Circulatory or metabolic compromise, e.g. diabetes, malnutrition, small vessel disease, and morbid obesity; **OR**
- Dehisced wounds of significant size.

Patient Selection Criteria for Continuation of Powered NPWT

Based on review of available data, the Company may consider continuation of the powered negative pressure wound therapy (NPWT) system to be **eligible for coverage**** when patient selection criteria are met:

- NPWT is part of a comprehensive wound care program; **AND**
- Initial 2-week therapeutic trial resulted in documented objective improvements in the wound; **AND**
- Documented ongoing objective improvement in the wound during subsequent treatment includes:
 - Development and presence of healthy granulation tissue; **AND**
 - Progressive wound contracture and/or decreasing depth; **AND**
 - Commencement of epithelial spread from the wound margins.

Medical record documentation must include **all** of the following:

- Direct wound evaluation, assessment and management based on standardized wound criteria are performed by an appropriately licensed medical professional. (measurements are required and photographs might be requested for initial coverage requests); **AND**
- At least biweekly (every two weeks) documentation of quantitative measurements of changes in wound/ulcer dimensions and characteristics, including surface area, depth, and serial observations (photographs might be requested for continuing coverage requests); **AND**
- Absence of necrosis; **AND**
- Wound management including the application of treatments that maintain a moist wound environment; **AND**
- Comprehensive disease/condition-specific management programs that provide optimal wound healing environment; **AND**
- Assessment of and/or appropriate intervention to establish and maintain adequate nutritional status; **AND**
- Clinical need for use of vacuum assisted wound closure device in a Stage III or IV or problematic wounds.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company may consider vacuum assisted wound closure devices for the treatment of wounds when initial coverage criteria are not met to be **not medically necessary****.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Based on review of available data, the Company may consider vacuum assisted wound closure devices for the continuing treatment of wounds under any of the following conditions to be **not medically necessary**:**

- Continuation coverage criteria are not met; **OR**
- The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound, i.e. any measurable degree of wound healing has failed to occur over the prior 15- 30 days; **OR**
- The wound has developed evidence of wound complications contraindicating continued NPWT (see below); **OR**
- The wound has healed to the extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments (see below); **OR**
- The vacuum assisted wound closure device has been used for 60 days in the treatment of any wound. Coverage beyond 60 days will be given individual consideration based upon supplemental documentation.

Note: Continuation of healing during use of the NPWT system should be monitored on a frequency of not less than every 14 days. Complete healing of a wound would normally be anticipated if all bone, cartilage, tendons, and foreign material were completely covered, healthy granulation were present to within 5 mm of the surface, and the wound edges were reduced to 2 cm in width or diameter.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of NPWT systems for conditions noted by the U.S. Food and Drug Administration (FDA) as contraindications to be **investigational***, including but not limited to:

- Presence of necrotic tissue with eschar, if debridement is not attempted; **OR**
- Untreated osteomyelitis in the vicinity of the wound; **OR**
- Malignancy in the wound; **OR**
- Fistulae to an organ or body cavity within the vicinity of the wound; **OR**
- Exposed nerve, exposed anastomotic site, and exposed organ.

Based on review of available data, the Company considers single-use (disposable) NPWT systems (powered or non-powered), e.g., gauze based SNaP Wound Care System, PICO Single Use Negative Pressure Wound Therapy System, Prevena Incision Management System, for the treatment of acute or chronic wounds, including but not limited to diabetic, venous, surgical incisions, and traumatic wounds to be **investigational**.*

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Policy Guidelines

Contraindications to the use of NPWT systems include the following conditions as noted in a 2009 U.S. Food and Drug Administration (FDA) alert: necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulae, malignancy in the wound, exposed nerve, exposed anastomotic site, and exposed organ.

In a 2011 update, FDA noted additional deaths and injury reports with NPWT since 2009. Although rare, these complications can occur wherever NPWT systems are used, including hospitals, long-term care facilities, and at home. Bleeding was the cause of the most serious adverse events, including deaths. Most reports of wound infection were related to the retention of dressing pieces in the wounds. Recommendations for health care providers include the following: select individuals for NPWT carefully knowing that NPWT systems are contraindicated for certain wound types, and individual risk factors must be thoroughly considered before use; assure that the individual is monitored frequently in an appropriate care setting by a trained practitioner; be aware of complications associated with dressing changes such as infection and bleeding; be vigilant for potentially life-threatening complications, such as bleeding; and be prepared to take prompt action if they occur. The FDA reported that the safety and effectiveness of NPWT systems in newborns, infants, and children had not been established and, currently, there are no NPWT systems cleared for use in these populations.

Continuation of healing during use of the NPWT system should be monitored on a frequency of not less than every 14 days.

Complete healing of a wound would normally be anticipated if all bone, cartilage, tendons, and foreign material were completely covered, healthy granulation were present to within 5 mm of the surface, and the wound edges were reduced to 2 cm in width or diameter.

Powered NPWT systems should be used as part of a comprehensive wound care program that includes attention to other factors that impact wound healing such as diabetes control, nutritional status, and relief of pressure.

The focus of these policy statements and guidelines is for the use of NPWT in the outpatient setting.

Background/Overview

Chronic Wounds

Management

The management and treatment of chronic wounds, including decubitus ulcers, is challenging. Furthermore, certain racial and ethnic groups, including African Americans, Hispanics, and Native Americans, experience higher diabetes prevalence, contributing to disparities in the risk for diabetic ulcers; these disparities are exacerbated when inequalities in access to health care result in delayed diagnosis and management.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Most chronic wounds will heal only if the underlying cause (ie, venous stasis, pressure, infection) is addressed. Also, cleaning the wound to remove nonviable tissue, microorganisms, and foreign bodies is essential to create optimal conditions for either re-epithelialization (ie, healing by secondary intention) or preparation for wound closure with skin grafts or flaps (ie, healing by primary intention). Therefore, debridement, irrigation, whirlpool treatments, and wet-to-dry dressings are common components of chronic wound care.

Negative pressure wound therapy involves the use of a negative pressure therapy or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue. The devices may also be used as an adjunct to surgical therapy or as an alternative to surgery in a debilitated patient. Although the exact mechanism has not been elucidated, it is hypothesized that negative pressure contributes to wound healing by removing excess interstitial fluid, increasing the vascularity of the wound, reducing edema, and/or creating beneficial mechanical forces that lead to cell growth and expansion.

A nonpowered (mechanical) NPWT system has also been developed; the Smart Negative Pressure Wound Care System is portable and lightweight (3 oz) and can be worn underneath clothing. This system consists of a cartridge, dressing, and strap; the cartridge acts as the negative pressure source. The system is reported to generate negative pressure levels similar to other NPWT systems. This system is fully disposable.

The focus of this evidence review is the use of NPWT in the outpatient setting. It is recognized that patients may begin using the device in the inpatient setting as they transition to the outpatient setting.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Negative pressure therapy or suction devices cleared by the U.S. FDA for treating chronic wounds include, but are not limited to: Vacuum-Assisted Closure[®] Therapy (V.A.C., also known as negative pressure wound therapy; 3M[™]/KCI)[‡]; Versatile 1[™] (V1) Wound Vacuum System (Blue Sky Medical), RENASYS[™] EZ PLUS (Smith & Nephew), Foryou NPWT NP32 Device (Foryou Medical Electronics), SVED[®] (Cardinal Health), and PICO Single Use Negative Pressure Wound Therapy System (Smith & Nephew).

Portable systems include the RENASYS[™] GO (Smith & Nephew), XLR8 PLUS (Genadyne Biotechnologies), extriCARE[®] 2400 NPWT System (Devon Medical), the V.A.C. Via[™] (KCI), NPWT PRO to GO (Cardinal Health), and the PICO Single Use Negative Pressure Wound Therapy System (Smith & Nephew). The Prevena[™] Incision Management System (KCI) is designed specifically for closed surgical incisions.

A nonpowered NPWT device, the SNaP[®] Wound Care System (now SNAP[™] Therapy System) (3M[™] / previously Spiracur, acquired by Acelity in 2015), was cleared for marketing by the FDA in 2009 through the 510(k) pathway (K081406) and is designed to remove small amounts of exudate from chronic, traumatic, dehiscent, acute, or subacute wounds and diabetic and pressure ulcers.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Examples of disposable negative pressure wound therapy devices include (not all-inclusive):

- 3M™ Prevena™ Incision Management System
- 3M™ Prevena Restor™ Incision Management System
- Prevena™ Plus Duo Incision Management System
- Avance® Solo
- extriCARE® 3000, extriCARE® 2400 NPWT System (Devon Medical)
- NEXA™ NPWT System
- AVELLE Negative Pressure Wound Therapy System
- V.A.C. Via™ Negative Pressure Wound Therapy System (KCI)
- Cardinal Health™ disposable systems: PRO, PRO TO GO, ALLY™, ALLY TO GO™
- Invia Motion® Negative Pressure Wound Therapy System
- myNeWT Negative Pressure Wound Therapy System
- PICO™ Single Use Negative Pressure Wound Therapy System (Smith & Nephew); Pico 7 and Pico 14 (for 7 days or 14-day pump wear time)
- NPseal Negative Pressure Advanced System (Guard Medical Inc)
- UNO Negative Pressure Wound Therapy System; UNO 7, UNO 15, UNO 30
- SNaP® Wound Care System/ 3M™ SNAP™ Therapy System
- Genadyne XLR8+

Negative pressure wound therapy devices with instillation include the V.A.C. VERAFLOR™ Therapy device (3M™/KCI/Acelity)™. It was cleared for marketing in 2011 by the FDA through the 510(k) pathway (K103156) and is designed to allow for controlled delivery and drainage of topical antiseptic and antimicrobial wound treatment solutions and suspensions. It is to be used with the V.A.C. Ulta unit, which is commercially marketed for use in the hospital setting. Instillation is also available with Simultaneous Irrigation™ Technology tubing sets (Cardinal Health) for use with Cardinal Health SVED® and PRO NPWT devices, however, its use is not indicated for use in a home care setting (K161418).

No NPWT device has been cleared for use in infants and children.

In November 2009, the FDA issued an alert concerning complications and deaths associated with NPWT systems. An updated alert was issued in February 2011.

FDA product code: OMP.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Negative pressure wound therapy involves the use of negative pressure or suction devices to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue and wound healing.

Summary of Evidence

For individuals who have diabetic lower-extremity ulcers or amputation wounds who receive outpatient NPWT, the evidence includes systematic reviews of randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, morbid events, quality of life (QOL), and treatment-related morbidity. There was a higher rate of wound healing and fewer amputations with NPWT, although the studies were at risk of bias due to lack of blinding. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have diabetic lower-extremity ulcers or amputation wounds who receive portable, single-use outpatient NPWT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. A 2019 RCT compared the PICO device with standard NPWT. In this study, the PICO device demonstrated noninferiority for wound area reduction. A statistically significant benefit in complete wound closure was noted for patients with diabetic foot ulcers, but was not duplicated in the per protocol population due to a high number of exclusions. One study of the SNaP System showed noninferiority to a V.A.C. device for wound size reduction. No significant difference in complete wound closure was reported. Interpretation of this study is limited by a high loss to follow-up. Well-designed comparative studies with larger numbers of patients powered to detect differences in complete wound closure are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic pressure ulcers who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. All trials are of low quality and at high risk of bias. Also, most study populations were treated in inpatient settings. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive outpatient NPWT, the evidence includes an RCT and a systematic review. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. A single RCT in patients with nonhealing leg ulcers who were treated with skin grafts found a faster rate of healing with NPWT when used in the inpatient setting. No studies were identified on the effectiveness of NPWT as a primary treatment for leg ulcers or for the use of NPWT in the outpatient setting. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive portable, single-use outpatient NPWT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. A 2019 RCT compared the PICO device with standard NPWT. In this study, the PICO device demonstrated noninferiority for

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

wound area reduction. No significant benefit in complete wound closure was found in patients with venous ulcers. One study of the SNaP System showed noninferiority to a V.A.C. device for wound size reduction. A subgroup analysis of this study found a significant difference in complete wound closure for patients with venous ulcers. However, interpretation of this study is limited by a high loss to follow-up and lack of a control group treated with standard dressings. Well-designed comparative studies with larger numbers of patients powered to detect differences in complete wound closure are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have burn wounds who receive outpatient NPWT, the evidence includes RCTs, systematic reviews, and case series. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. An interim report of an RCT evaluating NPWT in partial-thickness burns, summarized in a Cochrane review, did not permit conclusions on the efficacy of NPWT for this indication. A separate RCT comparing NPWT with split-skin grafts in patients with full-thickness burns did not show differences in graft take and wound epithelialization. A retrospective case series reported good functional outcomes for most patients who were treated with NPWT at a single center. A meta-analysis of international trials found that NPWT was associated with faster healing times; however, the analysis was limited by substantial heterogeneity, inconsistent intervention protocols, and a moderate risk of bias across several studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have traumatic or surgical wounds who receive NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. Systematic reviews of RCTs in patients with surgical wounds have generally found lower risk of SSI; however, many studies are limited to short-term use of NPWT limiting applicability to the outpatient setting. For patients with traumatic wounds, a Cochrane review failed to find significant improvement in patients treated with NPWT. In 2025 multicenter randomized controlled trial of NPWT versus usual care in patients with lower limb surgical wound healing by secondary intention (SWHSI-2), including those with complications of diabetes, NPWT did not reduce the time to wound healing compared to standard dressings. There were 448 adverse events, of which 14 were serious (nine participants in the NPWT group and five participants in the usual care group); 124 were deemed potentially related to treatment. NPWT was found not to be cost-effective compared with usual care. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have traumatic or surgical wounds who receive portable, single-use outpatient NPWT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. The PICO device was studied in an adequately powered but unblinded RCT of combined in- and outpatient use after total joint arthroplasty, and 2 single-center RCTs of combined in- and outpatient use after cesarean delivery in women with obesity or other risk factors for poor wound healing. The evidence base for the Prevena System in the outpatient setting is not sufficiently robust for conclusions on efficacy to be drawn. Well-designed comparative studies with larger numbers of patients treated in an outpatient setting

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information

Overall, the evidence from comparative clinical trials has demonstrated there is a subset of problematic wounds for which the use of NPWT may provide a significant clinical benefit. However, due to clinical variability and limited data, it is not possible to determine prospectively which wounds are most likely to respond favorably to NPWT. In addition, clinical input supports a therapeutic trial of NPWT for chronic pressure ulcers that have failed to heal, for traumatic or surgical wounds that have failed to close when there is exposed bone, cartilage, tendon, or foreign material within the wound, and for nonhealing wounds in patients with underlying clinical conditions known to negatively impact wound healing. Therefore, a therapeutic trial of NPWT of not less than 14 days may be considered medically necessary for chronic wounds that have failed to heal, despite intense conventional wound therapy for at least 90 days, or for wounds of at least 30 days that have a high probability of failure to heal due to compounding factors involving the wound and the patient. For continued use of NPWT beyond 14 days to meet criteria for medical necessity, there must be objective evidence of wound healing, such as the development of healthy granulation tissue and progressive wound contracture.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2010 Input

In response to requests, input was received from 2 physician specialty societies and 3 academic medical centers while this policy was under review in 2010. The input was near uniform in support of a therapeutic trial of NPWT for chronic pressure ulcers that have failed to heal; for traumatic or surgical wounds that have failed to close when there is exposed bone, cartilage, tendon, or foreign material within the wound; and for nonhealing wounds in patients with underlying clinical conditions known to negatively impact wound healing. Most input affirmed that therapeutic trials of NPWT for other acute or chronic wounds would not be medically necessary.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) 2022 guidelines for prevention of surgical site infections after major extremity trauma included recommendations for NPWT. The recommendations from AAOS do not support the continued use of NPWT in patients undergoing fracture fixation due to similar outcomes to standard wound care but with increased healthcare burden. In patients with high-risk surgical incisions the AAOS recommends that limited evidence suggests NPWT may be an option; however, its use will be influenced by cost. Importantly, these guidelines do not specifically address use in the outpatient setting.

American College of Physicians

In 2015, the American College of Physicians published guidelines (now inactive) on the treatment of pressure ulcers. The guidelines stated there was low-quality evidence that the overall treatment effect of NPWT did not differ from the standard of care. Of note, the American College of Physicians considers these guidelines inactive since they are more than 5 years old.

Association for the Advancement of Wound Care

In 2010, the Association for the Advancement of Wound Care (AAWC) published guidelines on the care of pressure ulcers. Negative pressure wound therapy was included as a potential second-line intervention if first-line treatments did not result in wound healing (level B evidence). The guidelines indicated that patients must be selected carefully for this procedure. The guidelines were updated in 2014 with additional validation.

In 2010, the AAWC published guidelines on the care of venous ulcers. The guidelines listed NPWT as a potential adjunctive therapy if conservative therapy does not work in 30 days. The guidelines noted there is limited evidence for NPWT (level B) compared with other adjunctive therapies.

International Multidisciplinary Consensus Recommendations

Willy et al (2017) presented evidence-based consensus guidelines on the use of closed incision negative pressure therapy (ciNPT) following surgery. Among the studies found were 100 randomized controlled studies on ciNPT, most of which found an association between the use of ciNPT and improved outcomes. Based on the evidence, the consensus panel recommended that surgeons evaluate risk in patients before surgery to determine whether patient comorbidities (ie, obesity or diabetes) or the nature of the surgery presents an increased danger of infection. In such cases, the panel recommended the use of ciNPT.

Infectious Diseases Society of America and Surgical Infection Society

A 2023 guideline from the Society for the diagnosis and treatment of diabetic-related foot infections (DFIs) makes the following recommendation relevant to NPWT: "We suggest *not* using the following treatments to address DFIs: (a) adjunctive granulocyte colony-stimulating factor (G-CSF) treatment or (b) topical antiseptics, silver preparations, honey, bacteriophage therapy, or negative-pressure wound therapy (with or without instillation)." This was graded as a conditional recommendation with low-quality evidence.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Wound Healing Society

The 2023 Wound Healing Society (WHS) guideline for the treatment of pressure ulcers makes the following recommendations:

"Incisional negative pressure wound therapy (iNPWT) may reduce post-operative complications after flap reconstruction for pressure ulcers."

"Negative pressure wound therapy (NPWT) is a safe and effective treatment for chronic stage III or IV pressure ulcers."

The guideline does not provide further information on the outpatient use of NPWT devices.

National Institute for Health and Care Excellence

In 2013, NICE issued guidance on NPWT for surgical wounds, concluding that "current evidence on the safety and efficacy of negative pressure wound therapy (NPWT) for the open abdomen is adequate to support the use of this procedure."

A 2015 NICE guidance on diabetic foot problems, updated in October 2019, has recommended consideration of NPWT after surgical debridement for diabetic foot ulcers on the advice of the multidisciplinary foot care service. It was noted that the evidence reviewed for NPWT was limited and of low quality, and that it would be useful to have more evidence for this commonly used treatment.

In 2014, NICE issued guidance on the prevention and management of pressure ulcers. The guidance stated, "Do not routinely offer adults negative pressure wound therapy to treat a pressure ulcer, unless it is necessary to reduce the number of dressing changes (for example, in a wound with a large amount of exudate)." Also, the guidance did not recommend NPWT for neonates, infants, or children.

A 2019 NICE guidance recommends the use of the PICO7 negative pressure wound dressing for closed surgical incisions due to their association with fewer surgical site infections and seromas compared to standard wound dressings. The device is considered an option for those who are at high risk for surgical site infections, which may be driven by several factors (eg, age, underlying illness, obesity, smoking, wound classification, and site and complexity of procedure). The device is recommended for those with low to moderate levels of wound exudate who will require infrequent dressing changes.

A 2021 NICE guidance on cesarean birth recommends considering the use of NPWT for women with a body mass index ≥ 35 kg/m² to reduce the risk of wound infections. Routine use of NPWT following cesarean delivery is not recommended. These recommendations were unchanged in a 2025 update to this guidance.

A 2021 NICE guidance states that while the V.A.C. Veraflo Therapy system shows promise in the treatment of acute infected or chronic non-healing wounds, there is not enough high-quality evidence

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

to support the case for routine adoption. The guidance recommends research in the form of an RCT comparing the V.A.C. Veraflo Therapy system (NPWT with wound instillation) to NPWT alone.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT05389410	Comparison of Surgical Wound Healing and Complications Following Revision Hip and Knee Replacements, utilizing a 7-day Versus 14-day Negative Pressure Wound Therapy (NPWT) Dressing. A Randomized Controlled Trial	164	Feb 2027
NCT05615844	A Randomized Controlled Trial Comparing Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy for the Management of Severe Open Tibia Fracture Wounds	312	Oct 2027
NCT01913132	PICO Versus Standard Dressing Above Groin Incisions After Vascular Surgery - A Prospective Randomized Trial	644	Dec 2026
<i>Unknown Status</i>			
NCT05877378	Efficacy of PICO Single-use System in Chronic Ulcers	42	Apr 2024
NCT05064696	Prospective Comparison of Wound Complications After Anterior Total Ankle Arthroplasty with and Without PICO Negative Pressure Incisional Dressing	150	Sep 2025
NCT05071443	Vacuum-Assisted Closure for Necrotizing Soft Tissue infections	130	Jun 2025

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT03773575 ^a	Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications (PREVENA-AMP)	440	Aug 2024
NCT02813161	A Real World, Observational Registry of Diabetic Foot Ulcers and Quality of Care in Clinical Practice (DFUR)	10,000	Feb 2025
<i>Unpublished</i>			
NCT03414762	PICO Negative Pressure Wound Therapy in Obese Women Undergoing Elective Cesarean Delivery	153	Sep 2022
NCT04584957	Prophylactic Negative Pressure Wound Therapy in Gynecologic Oncology: a Prospective Controlled Randomized Trial (GO-VAC)	196	Sep 2021
NCT03948412	Negative Pressure Wound Therapy (PREVENA) Versus Standard Dressings for Incision Management After Renal Transplant (IMPART)	500	Sep 2021
NCT01191567	Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life	200	Terminated
NCT02195310 ^a	The Use of Prevena TM Incision Management System on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences	342	Terminated

NCT: national clinical trial; NR: not reported.

^a Denotes industry-sponsored or cosponsored trial.

References

1. U.S. Food and Drug Administration. UPDATE on Serious Complications Associated with Negative Pressure Wound Therapy Systems: FDA Safety Communication. 2011 Feb; <http://wayback.archive-it.org/7993/20170722215801/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm244211.htm>. Accessed November 14, 2025.
2. Food and Drug Administration (FDA). Guidance for Industry. Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment. June 2006; <https://www.fda.gov/media/71278/download>.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

3. Rhee SM, Valle MF, Wilson LM, et al. Negative Pressure Wound Therapy Technologies For Chronic Wound Care in the Home Setting. Evidence Report/Technology Assessment (Contract No. 290-201-200007-I) Rockville, MD: Agency for Healthcare Research and Quality; 2014.
4. Rhee SM, Valle MF, Wilson LM, et al. Negative pressure wound therapy technologies for chronic wound care in the home setting: A systematic review. *Wound Repair Regen.* 2015; 23(4): 506-17. PMID 25845268
5. Sullivan N, Snyder DL, Tipton K, et al. Technology assessment: Negative pressure wound therapy devices (Contract No. 290-2007-10063). Rockville, MD: Agency for Healthcare Research and Quality; 2009.
6. Dumville JC, Hinchliffe RJ, Cullum N, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. *Cochrane Database Syst Rev.* Oct 17 2013; (10): CD010318. PMID 24132761
7. Liu Z, Dumville JC, Hinchliffe RJ, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. *Cochrane Database Syst Rev.* Oct 17 2018; 10(10): CD010318. PMID 30328611
8. Wynn M, Freeman S. The efficacy of negative pressure wound therapy for diabetic foot ulcers: A systematised review. *J Tissue Viability.* Aug 2019; 28(3): 152-160. PMID 31056407
9. Chen L, Zhang S, Da J, et al. A systematic review and meta-analysis of efficacy and safety of negative pressure wound therapy in the treatment of diabetic foot ulcer. *Ann Palliat Med.* Oct 2021; 10(10): 10830-10839. PMID 34763444
10. Kirsner R, Dove C, Reyzelman A, et al. A prospective, randomized, controlled clinical trial on the efficacy of a single-use negative pressure wound therapy system, compared to traditional negative pressure wound therapy in the treatment of chronic ulcers of the lower extremities. *Wound Repair Regen.* Sep 2019; 27(5): 519-529. PMID 31087729
11. Kirsner RS, Zimnitsky D, Robinson M. A prospective, randomized, controlled clinical study on the effectiveness of a single-use negative pressure wound therapy system, compared to traditional negative pressure wound therapy in the treatment of diabetic ulcers of the lower extremities. *Wound Repair Regen.* Nov 2021; 29(6): 908-911. PMID 34525239
12. Armstrong DG, Marston WA, Reyzelman AM, et al. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. *Wound Repair Regen.* 2011; 19(2): 173-80. PMID 21362084
13. Armstrong DG, Marston WA, Reyzelman AM, et al. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. *Wound Repair Regen.* 2012; 20(3): 332-41. PMID 22564228
14. Lerman B, Oldenbrook L, Eichstadt SL, et al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. *Plast Reconstr Surg.* Oct 2010; 126(4): 1253-1261. PMID 20885246
15. Shi J, Gao Y, Tian J, et al. Negative pressure wound therapy for treating pressure ulcers. *Cochrane Database Syst Rev.* May 26 2023; 5(5): CD011334. PMID 37232410
16. Wanner MB, Schwarzl F, Strub B, et al. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. *Scand J Plast Reconstr Surg Hand Surg.* 2003; 37(1): 28-33. PMID 12625392

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

17. Dumville JC, Land L, Evans D, et al. Negative pressure wound therapy for treating leg ulcers. *Cochrane Database Syst Rev*. Jul 14 2015; 2015(7): CD011354. PMID 26171910
18. Vuerstaek JD, Vainas T, Wuite J, et al. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. *J Vasc Surg*. Nov 2006; 44(5): 1029-37; discussion 1038. PMID 17000077
19. Marston WA, Armstrong DG, Reyzelman AM, et al. A Multicenter Randomized Controlled Trial Comparing Treatment of Venous Leg Ulcers Using Mechanically Versus Electrically Powered Negative Pressure Wound Therapy. *Adv Wound Care (New Rochelle)*. Feb 01 2015; 4(2): 75-82. PMID 25713749
20. Lou J, Zhu X, Xiang Z, et al. The efficacy and safety of negative pressure wound therapy in paediatric burns: a systematic review and meta-analysis of randomized controlled trials. *BMC Pediatr*. Dec 18 2024; 24(1): 807. PMID 39696096
21. Dumville JC, Munson C, Christie J. Negative pressure wound therapy for partial-thickness burns. *Cochrane Database Syst Rev*. Dec 15 2014; 2014(12): CD006215. PMID 25500895
22. Bloemen MC, van der Wal MB, Verhaegen PD, et al. Clinical effectiveness of dermal substitution in burns by topical negative pressure: a multicenter randomized controlled trial. *Wound Repair Regen*. 2012; 20(6): 797-805. PMID 23110478
23. Krug E, Berg L, Lee C, et al. Evidence-based recommendations for the use of Negative Pressure Wound Therapy in traumatic wounds and reconstructive surgery: steps towards an international consensus. *Injury*. Feb 2011; 42 Suppl 1: S1-12. PMID 21316515
24. Ehrh D, Heidekrueger PI, Broer PN, et al. Topical Negative Pressure Wound Therapy of Burned Hands: Functional Outcomes. *J Burn Care Res*. Jan 01 2018; 39(1): 121-128. PMID 28368916
25. Norman G, Shi C, Goh EL, et al. Negative pressure wound therapy for surgical wounds healing by primary closure. *Cochrane Database Syst Rev*. Apr 26 2022; 4(4): CD009261. PMID 35471497
26. Li HZ, Xu XH, Wang DW, et al. Negative pressure wound therapy for surgical site infections: a systematic review and meta-analysis of randomized controlled trials. *Clin Microbiol Infect*. Nov 2019; 25(11): 1328-1338. PMID 31220604
27. De Vries FEE, Wallert ED, Solomkin JS, et al. A systematic review and meta-analysis including GRADE qualification of the risk of surgical site infections after prophylactic negative pressure wound therapy compared with conventional dressings in clean and contaminated surgery. *Medicine (Baltimore)*. Sep 2016; 95(36): e4673. PMID 27603360
28. Iheozor-Ejiofor Z, Newton K, Dumville JC, et al. Negative pressure wound therapy for open traumatic wounds. *Cochrane Database Syst Rev*. Jul 03 2018; 7(7): CD012522. PMID 29969521
29. Stannard JP, Volgas DA, McGwin G, et al. Incisional negative pressure wound therapy after high-risk lower extremity fractures. *J Orthop Trauma*. Jan 2012; 26(1): 37-42. PMID 21804414
30. Costa ML, Achten J, Bruce J, et al. Effect of Negative Pressure Wound Therapy vs Standard Wound Management on 12-Month Disability Among Adults With Severe Open Fracture of the Lower Limb: The WOLFF Randomized Clinical Trial. *JAMA*. Jun 12 2018; 319(22): 2280-2288. PMID 29896626
31. Seidel D, Diedrich S, Herrle F, et al. Negative Pressure Wound Therapy vs Conventional Wound Treatment in Subcutaneous Abdominal Wound Healing Impairment: The SAWHI Randomized Clinical Trial. *JAMA Surg*. Jun 01 2020; 155(6): 469-478. PMID 32293657

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

32. Stannard JP, Robinson JT, Anderson ER, et al. Negative pressure wound therapy to treat hematomas and surgical incisions following high-energy trauma. *J Trauma*. Jun 2006; 60(6): 1301-6. PMID 16766975
33. Monsen C, Acosta S, Mani K, et al. A randomised study of NPWT closure versus alginate dressings in peri-vascular groin infections: quality of life, pain and cost. *J Wound Care*. Jun 2015; 24(6): 252, 254-6, 258-0. PMID 26075373
34. Costa ML, Achten J, Parsons NR. Five-year outcomes for patients sustaining severe fractures of the lower limb : mid-term results from the Wound management for Open Lower Limb Fracture (WOLLF) trial. *Bone Joint J*. May 2022; 104-B(5): 633-639. PMID 35491582
35. Seidel D, Lefering R. NPWT Resource Use Compared With Conventional Wound Treatment in Subcutaneous Abdominal Wounds With Healing Impairment After Surgery: SAWHI Randomized Clinical Trial Results. *Ann Surg*. Feb 01 2022; 275(2): e290-e298. PMID 34117147
36. Karlakki SL, Hamad AK, Whittall C, et al. Incisional negative pressure wound therapy dressings (iNPWTd) in routine primary hip and knee arthroplasties: A randomised controlled trial. *Bone Joint Res*. Aug 2016; 5(8): 328-37. PMID 27496913
37. Peterson AT, Bakaysa SL, Driscoll JM, et al. Randomized controlled trial of single-use negative-pressure wound therapy dressings in morbidly obese patients undergoing cesarean delivery. *Am J Obstet Gynecol MFM*. Sep 2021; 3(5): 100410. PMID 34058423
38. Gonzalez MG, Barske ME, Kjellsson KB, et al. Topical negative pressure wound therapy to prevent wound complications following caesarean delivery in high-risk obstetric patients: A randomised controlled trial. *Aust N Z J Obstet Gynaecol*. Aug 2023; 63(4): 516-520. PMID 37140175
39. Pauser J, Nordmeyer M, Biber R, et al. Incisional negative pressure wound therapy after hemiarthroplasty for femoral neck fractures - reduction of wound complications. *Int Wound J*. Oct 2016; 13(5): 663-7. PMID 25125244
40. Murphy PB, Knowles S, Chadi SA, et al. Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections (NEPTUNE): A Randomized Controlled Trial. *Ann Surg*. Jul 2019; 270(1): 38-42. PMID 30499799
41. Hussamy DJ, Wortman AC, McIntire DD, et al. Closed Incision Negative Pressure Therapy in Morbidly Obese Women Undergoing Cesarean Delivery: A Randomized Controlled Trial. *Obstet Gynecol*. Oct 2019; 134(4): 781-789. PMID 31503147
42. Tuuli MG, Liu J, Tita ATN, et al. Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial. *JAMA*. Sep 22 2020; 324(12): 1180-1189. PMID 32960242
43. Bertges DJ, Smith L, Scully RE, et al. A multicenter, prospective randomized trial of negative pressure wound therapy for infrainguinal revascularization with a groin incision. *J Vasc Surg*. Jul 2021; 74(1): 257-267.e1. PMID 33548422
44. Ceppa EP, Kim RC, Niedzwiecki D, et al. Closed Incision Negative Pressure Therapy to Reduce Surgical Site Infection in High-Risk Gastrointestinal Surgery: A Randomized Controlled Trial. *J Am Coll Surg*. Apr 01 2023; 236(4): 698-708. PMID 36728375
45. American Academy of Orthopaedic Surgeons. Prevention of Surgical Site Infections After Major Extremity Trauma Evidence-Based Clinical Practice Guideline. <https://www.aaos.org/quality/quality-programs/clinical-practice-guidelines/>. Published 03/21/22.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

46. Qaseem A, Humphrey LL, Forciea MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* Mar 03 2015; 162(5): 370-9. PMID 25732279
47. Association for the Advancement of Wound Care (AAWC). International Consolidated Venous Ulcer Guideline (ICVUG). Update of AAWC Venous Ulcer Guideline, 2005 and 2010. 2015; <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>.
48. Willy C, Agarwal A, Andersen CA, et al. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. *Int Wound J.* Apr 2017; 14(2): 385-398. PMID 27170231
49. Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). *Diabetes Metab Res Rev.* Mar 2024; 40(3): e3687. PMID 37779323
50. Gould LJ, Alderden J, Aslam R, et al. WHS guidelines for the treatment of pressure ulcers-2023 update. *Wound Repair Regen.* 2024; 32(1): 6-33. PMID 37970711
51. National Institute for Health and Care Excellence (NICE). Negative Pressure Wound Therapy for the Open Abdomen [IPG467]. 2013; <https://www.nice.org.uk/guidance/ipg467>.
52. National Institute for Health and Care Excellence (NICE). Diabetic Foot Problems: Prevention and Management [NG19]. Published August 2015; Updated October 2019; <https://www.nice.org.uk/guidance/ng19/evidence>.
53. National Institute for Health and Care Excellence (NICE). Pressure ulcers: prevention and management [CG179]. 2014; <https://www.nice.org.uk/guidance/cg179>.
54. National Institute for Health and Care Excellence (NICE). PICO negative pressure wound dressings for closed surgical incisions [MTG43]. 2019; <https://www.nice.org.uk/guidance/mtg43>.
55. National Institute for Health and Care Excellence (NICE). Cesarean birth [NG192]. Published: March 2021. Updated: July 2025; <https://www.nice.org.uk/guidance/ng192>.
56. National Institute for Health and Care Excellence (NICE). The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal [MTG54]. 2021; <https://www.nice.org.uk/guidance/mtg54>.
57. Arundel C, Mandefield L, Fairhurst C, et al. Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2):an open-label, multicentre, parallel-group, randomised controlled trial. *Lancet.* 2025;405(10490):1689-1699. doi:10.1016/S0140-6736(25)00143-6

Policy History

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

02/20/2003 Medical Policy Committee review

04/14/2003 Managed Care Advisory Council approval

01/31/2004 Medical Director review

02/17/2004 Medical Policy Committee review. Format revision. No substance change to policy.

02/23/2004 Managed Care Advisory Council approval

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

02/01/2005	Medical Director review
02/15/2005	Medical Policy Committee review
03/07/2005	Managed Care Advisory Council approval
03/09/2006	Medical Director review
03/15/2006	Medical Policy Committee review. Format revision. Coverage eligibility unchanged.
04/05/2006	Medical Director review
04/19/2006	Medical Policy Committee approval
07/07/2006	Format revision; including, addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged
03/14/2007	Medical Director review
03/21/2007	Medical Policy Committee approval. Coverage eligibility unchanged.
03/12/2008	Medical Director review
03/19/2008	Medical Policy Committee approval. Coverage eligibility unchanged.
04/02/2008	Medical Director review
04/16/2008	Medical Policy Committee approval. No change to coverage eligibility.
04/02/2009	Medical Director review
04/15/2009	Medical Policy Committee approval. No change to coverage eligibility.
04/08/2010	Medical Director review
04/21/2010	Medical Policy Committee approval. No change to coverage eligibility.
04/07/2011	Medical Policy Committee review
04/13/2011	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/12/2012	Medical Policy Committee review
04/25/2012	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/04/2013	Medical Policy Committee review
04/24/2013	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/03/2014	Medical Policy Committee review
04/23/2014	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/02/2015	Medical Policy Committee review
04/20/2015	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/07/2016	Medical Policy Committee review
04/20/2016	Medical Policy Implementation Committee approval. No change to coverage eligibility.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
04/06/2017	Medical Policy Committee review
04/19/2017	Medical Policy Implementation Committee approval. Added continuation approval criteria and a new investigational statement.
04/05/2018	Medical Policy Committee review

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

04/18/2018 Medical Policy Implementation Committee approval. Criteria clarified documentation every 2 weeks for recertification.

04/04/2019 Medical Policy Committee review

04/24/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

04/02/2020 Medical Policy Committee review

04/08/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

04/01/2021 Medical Policy Committee review

04/14/2021 Medical Policy Implementation Committee approval. All of the coverage statements were revised. See below:

Eligible statement revised to:

Based on review of available data, the Company may consider powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors (e.g. diabetes, nutrition, relief of pressure), to be **eligible for coverage**** when patient selection criteria are met.

Patient Selection Criteria for Initial 2-week Therapeutic Trial

Coverage eligibility will be considered when any of the following criteria are met:

- Stage III or IV chronic open wounds (diabetic or pressure ulcers) present for at least 30 days that have failed to heal despite optimal wound care when there is high-volume drainage that interferes with healing and/or when standard dressing cannot be maintained; or
- Traumatic or surgical wounds where there has been a failure of immediate or delayed primary closure, AND there is exposed bone, cartilage, tendon, or foreign material within the wound; or
- Other problematic wounds in patients with clinical conditions known to negatively impact wound healing, which are nonhealing (at least 30 days) despite optimal wound care, and require accelerated formation of granulation tissue that cannot be achieved by other available topical wound treatments, including:
 - Significant risk of infection, such as wound location
 - Immunocompromised status
 - Circulatory or metabolic compromise, e.g. diabetes, malnutrition, small vessel disease, and morbid obesity
 - Dehiscent wounds of significant size

Patient Selection Criteria for Continuation of Powered NPWT

Continuation of the powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program, may be considered **eligible for coverage**** following an initial 2-week therapeutic trial if the treatment trial has resulted in documented objective improvements in the wound, and if there is ongoing objective improvement during subsequent treatment. Objective improvements in the wound should include the development and presence of healthy granulation tissue, progressive wound contracture and decreasing depth, and/or the commencement of epithelial spread from the wound margins.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

Medical record documentation must include all of the following:

- Direct wound evaluation, assessment and management based on standardized wound criteria are performed by an appropriately licensed medical professional. (measurements are required and photographs might be requested for initial coverage requests); and
- At least biweekly (every two weeks) documentation of quantitative measurements of changes in wound/ulcer dimensions and characteristics, including surface area, depth, and serial observations (photographs might be requested for continuing coverage requests); and
- Absence of necrosis; and
- Wound management including the application of treatments that maintain a moist wound environment; and
- Comprehensive disease/condition-specific management programs that provide optimal wound healing environment; and
- Assessment of and/or appropriate intervention to establish and maintain adequate nutritional status; and
- Clinical need for use of vacuum assisted wound closure device in a Stage III or IV or problematic wounds.

Not Medically Necessary statement revised to:

Based on review of available data, the Company may consider vacuum assisted wound closure devices for the treatment of wounds to be **not medically necessary**** under any of the following conditions:

- Initial coverage criteria are not met; or
- There is presence of necrotic tissue with eschar, if debridement is not attempted; or
- Untreated osteomyelitis exists in the vicinity of the wound; or
- Cancer is present in the wound; or
- There is the presence of a fistula to an organ or body cavity within the vicinity.

Based on review of available data, the Company may consider vacuum assisted wound closure devices for the continuing treatment of wounds to be **not medically necessary**** under any of the following conditions:

- Initial coverage criteria are no longer met; or
- The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound (i.e. any measurable degree of wound healing has failed to occur over the prior 15- 30 days); or
- The wound has developed evidence of wound complications contraindicating continued NPWT (see below); or
- The wound has healed to the extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments (see below); or

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

- The vacuum assisted wound closure device has been used for 60 days in the treatment of any wound. Coverage beyond 60 days will be given individual consideration based upon supplemental documentation.

Investigational section revised to :

Based on review of available data, the Company considers use of powered or non-powered portable, disposable (single-use) NPWT systems and all non-powered NPWT systems (e.g. gauze based SNaP Wound Care System, PICO Single Use Negative Pressure Wound Therapy System, Prevena Incision Management System) for the treatment of acute or chronic wounds, including but not limited to diabetic, venous, surgical incisions, and traumatic wounds to be **investigational**.*

04/07/2022 Medical Policy Committee review

04/13/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

04/06/2023 Medical Policy Committee review

04/12/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged. Added “single-use (disposable) NPWT systems (powered or non-powered)” to investigational statement.

04/27/2023 Coding update. Updated FDA section to include only disposable systems.

04/04/2024 Medical Policy Committee review

04/10/2024 Medical Policy Implementation Committee approval. No change to coverage.

04/03/2025 Medical Policy Committee review

04/09/2025 Medical Policy Implementation Committee approval. Coverage eligibility unchanged. FDA section updated.

04/02/2026 Medical Policy Committee review

04/10/2026 Medical Policy Implementation Committee approval. Added a statement to deny not medically necessary if criteria are not met. Moved the following from not medically necessary to investigational: “Based on review of available data, the Company considers the use of NPWT systems for conditions noted by the U.S. Food and Drug Administration (FDA) as a contraindications to be **investigational***, including but not limited to:

- Presence of necrotic tissue with eschar, if debridement is not attempted; OR
- Untreated osteomyelitis in the vicinity of the wound; OR
- Malignancy in the wound; OR
- Fistulae to an organ or body cavity within the vicinity of the wound; OR
- Exposed nerve, exposed anastomotic site, and exposed organ.”

Added “Based on review of available data, the Company may consider continuation of the powered negative pressure wound therapy (NPWT) system to be **eligible for coverage**** when patient selection criteria are met:

- NPWT is part of a comprehensive wound care program; **AND**
- Initial 2-week therapeutic trial resulted in documented objective improvements in the wound; **AND**
- Documented ongoing objective improvement in the wound during subsequent treatment includes:

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

- Development and presence of healthy granulation tissue; **AND**
- Progressive wound contracture and/or decreasing depth; **AND**
- Commencement of epithelial spread from the wound margins.”

Added Patient Selection Criteria for Initial 2-Week Trial of Powered NPWT with revised criteria. Added Genadyne XLR8+ to list of disposable devices.

Next Scheduled Review Date: 04/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	97605, 97606, 97607, 97608
HCPCS	A6550, A9272, E2402, K0743, K0744, K0745, K0746
ICD-10 Diagnosis	All Related Diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

Vacuum-Assisted Closure of Chronic Wounds (Negative Pressure Wound Therapy)

Policy # 00132

Original Effective Date: 04/14/2003

Current Effective Date: 05/01/2026

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.